brontictuzumab

Overview

Brontictuzumab is an anti-NOTCH1 monoclonal antibody that inhibits NOTCH1 signaling. It is an experimental/investigational agent (corpus-grown; not confirmed in a canonical drug ontology). The drug was developed as a candidate intervention for cancers harboring activating NOTCH1 mutations, particularly adenoid cystic carcinoma (AdCC), based on evidence that activating NOTCH1 mutations identify an AdCC subset with bone/liver metastatic propensity and potential responsiveness to NOTCH1 inhibition.

Evidence in the corpus

• Cited as a candidate targeted therapy for NOTCH1-mutant sinonasal adenoid cystic carcinoma (ACYC): in an 88-case cohort, 3/21 sequenced tumors harbored truncating NOTCH1 mutations associated with solid/basaloid morphology and poor outcome (2/3 dead of disease); brontictuzumab was nominated as a Notch pathway intervention citing Ferrarotto et al. data showing NOTCH1-mutant AdCC has bone/liver metastatic propensity PMID:24418857

Resistance mechanisms

(No resistance data in the corpus.)

Cancer types (linked)

• ACYC — NOTCH1-mutant subset nominated as potential responders

Sources

This page was processed by crosslinker on 2026-05-09.